GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Evolutionary Genomics Inc (OTCPK:FNAM) » Definitions » Accounts Receivable

Evolutionary Genomics (Evolutionary Genomics) Accounts Receivable : $0.00 Mil (As of Dec. 2022)


View and export this data going back to 2011. Start your Free Trial

What is Evolutionary Genomics Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Evolutionary Genomics's accounts receivables for the quarter that ended in Dec. 2022 was $0.00 Mil.

Accounts receivable can be measured by Days Sales Outstanding.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Evolutionary Genomics's Net-Net Working Capital per share for the quarter that ended in Dec. 2022 was $-1.38.


Evolutionary Genomics Accounts Receivable Historical Data

The historical data trend for Evolutionary Genomics's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evolutionary Genomics Accounts Receivable Chart

Evolutionary Genomics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Accounts Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.04 0.01 - - -

Evolutionary Genomics Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Accounts Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Evolutionary Genomics Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.


Evolutionary Genomics Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Evolutionary Genomics's Days Sales Outstanding for the quarter that ended in Dec. 2022 is calculated as:

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Evolutionary Genomics's accounts receivable are only considered to be worth 75% of book value:

Evolutionary Genomics's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2022 is calculated as:

Net-Net Working Capital Per Share
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(0.577+0.75 * 0+0.5 * 0-7.946
-1.835-0)/6.65523
=-1.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.


Evolutionary Genomics Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Evolutionary Genomics's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Evolutionary Genomics (Evolutionary Genomics) Business Description

Traded in Other Exchanges
N/A
Address
4220 Morning Star Drive, Castle Rock, CO, USA, 80108
Evolutionary Genomics Inc is involved in the development of a technology platform, the Adapted Traits Platform (ATP), to identify commercially valuable genes that control important traits in animals and plants. It uses the ATP to identify genes to improve crop plant traits such as yield, sugar content, biomass, drought tolerance, and pest/disease resistance. The company's platform identifies key genes that have changed successfully to impart new or improved traits. Its primary source of revenue had been contract services revenue for research performed by it on behalf of other commercial entities and grant income received from governmental agencies, industry associations and grant-making foundations for research performed.
Executives
Steve B Warnecke director, 10 percent owner, officer: Chairman, CEO C/O TARGETED MEDICAL PHARMA, INC., 2980 BEVERLY GLEN CIRCLE, SUITE 301, LOS ANGELES CA 90077
Virginia P. Orndorff director 4580 AUGUSTA DR., BROOMFIELD CO 80023
Walter Messier officer: Secretary / Treasurer 1586 GOSHAWK DRIVE, LONGMONT CO 80504
Mark Virgil Boggess director 7857 E OAKBROOK CIR, MADISON WI 53717
Sanford Schwartz director, 10 percent owner 5353 MANHATTAN CIRCLE, STE 101, BOULDER CO 80303
Michael Friess director, 10 percent owner, officer: President/CEO 5353 MANHATTAN CIRCLE, STE 101, BOULDER CO 80303
Chloe M Divita director, officer: Secretary/Treasurer/CFO 5353 MANHATTAN CIRCLE, SUITE 101, BOULDER CO 80303

Evolutionary Genomics (Evolutionary Genomics) Headlines

No Headlines